Post job

Alexion Pharmaceuticals main competitors are Incyte, Vertex Pharmaceuticals, and Hoffmann-LA Roche Inc.

Competitor Summary. See how Alexion Pharmaceuticals compares to its main competitors:

  • Employees at Incyte earn more than most of the competitors, with an average yearly salary of $103,592.
Work at Alexion Pharmaceuticals?
Share your experience

Alexion Pharmaceuticals vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
1992
4.6
Boston, MA3$6.1B2,525
1988
4.9
Tarrytown, NY7$14.2B9,123
1989
4.6
Boston, MA5$11.0B3,400
1984
4.9
Marlborough, MA1$600.0M2,400
1849
4.5
New York, NY18$63.6B78,500
1999
3.7
Wayne, PA1$1.1M50
2004
4.9
Wayne, PA1$15.2B3,500
1987
4.6
Houston, TX3$291.6M660
Nanotherapeutics, Inc.
-
3.5
Alachua, FL1--
1991
4.8
Wilmington, DE1$4.2B1,600
2010
3.7
Willow Grove, PA1$3.0M266
2003
4.3
Oklahoma City, OK1$12.0M261
1993
4.1
Lexington, MA1-118
1896
4.9
Nutley, NJ2$60.9B101,200

Rate Alexion Pharmaceuticals' competitiveness in the market.

Zippia waving zebra

Alexion Pharmaceuticals salaries vs competitors

Among Alexion Pharmaceuticals competitors, employees at Incyte earn the most with an average yearly salary of $103,592.

Compare Alexion Pharmaceuticals salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Alexion Pharmaceuticals
$92,699$44.57-
Regeneron
$85,589$41.15-
Vertex Pharmaceuticals
$95,952$46.13-
Sunovion Pharmaceuticals
$67,270$32.34-
Pfizer
$70,868$34.07-
Octagon Research Solutions
$65,286$31.39-

Compare Alexion Pharmaceuticals job title salaries vs competitors

CompanyHighest salaryHourly salary
Alexion Pharmaceuticals
$103,401$49.71
Vertex Pharmaceuticals
$109,035$52.42
Pfizer
$106,840$51.37
Regeneron
$106,313$51.11
Incyte
$102,783$49.42
Hoffmann-LA Roche Inc
$98,107$47.17
Cyberonics
$94,056$45.22
Nanotherapeutics, Inc.
$89,922$43.23
Cytovance Biologics
$89,604$43.08
Acusphere
$87,332$41.99
Sunovion Pharmaceuticals
$87,068$41.86
Shire Pharmaceuticals Inc
$85,449$41.08
Octagon Research Solutions
$80,126$38.52
Azzur Group
$80,093$38.51

Do you work at Alexion Pharmaceuticals?

Is Alexion Pharmaceuticals able to compete effectively with similar companies?

Alexion Pharmaceuticals jobs

Alexion Pharmaceuticals demographics vs competitors

Compare gender at Alexion Pharmaceuticals vs competitors

Job titleMaleFemale
Sunovion Pharmaceuticals53%47%
Regeneron54%46%
Pfizer55%45%
Vertex Pharmaceuticals56%44%
Alexion Pharmaceuticals57%43%
Incyte59%41%

Compare race at Alexion Pharmaceuticals vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
61%13%9%12%4%
9.7
53%11%9%22%5%
9.3
55%18%10%13%4%
9.8
54%15%10%17%4%
9.8
56%14%7%17%6%
9.7
64%13%11%9%3%
9.8

Alexion Pharmaceuticals revenue vs competitors

Alexion Pharmaceuticals revenue is $6.1B. Among it's competitors, the company with the highest revenue is Pfizer, $63.6B . The company with the lowest revenue is Hoffmann-LA Roche Inc, $60.9B.

Alexion Pharmaceuticals and similar companies CEOs

CEOBio
Hervé Hoppenot
Incyte

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. During Mr. Hoppenot’s tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond oncology to include research and development in inflammation & autoimmunity. Under his leadership, revenue has increased by over 400 percent, which includes the addition of two new revenue streams; and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in 10 EU countries and Japan. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

Dr. Albert Bourla
Pfizer

Albert Bourla (Greek: Άλμπερτ Μπουρλά, born) is a Greek veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla served as chief operating officer.

Reshma Kewalramani M.d
Vertex Pharmaceuticals

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Antony Loebel is a Chief Medical Officer at Sunovion Pharmaceuticals Inc and is based in New York, New York.

Thomas Schinecker
Hoffmann-LA Roche Inc

Wang Yan are a Chief Executive Officer at Cytovance Biologics, President at Scientific Protein Labs Llc, and Board Member at Cytovance Biologics. They have worked as VP:Business Development at Scientific Protein Labs Llc.

Michael Khavinson
Azzur Group

Alexion Pharmaceuticals competitors FAQs

Search for jobs